Whole-Genome Sequencing to Predict Antimicrobial Susceptibility Profiles in Neisseria gonorrhoeae.
Neisseria gonorrhoeae
antimicrobial susceptibility testing
whole-genome sequencing
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
12 04 2023
12 04 2023
Historique:
received:
20
06
2022
accepted:
01
02
2023
pmc-release:
03
02
2024
medline:
14
4
2023
pubmed:
4
2
2023
entrez:
3
2
2023
Statut:
ppublish
Résumé
Neisseria gonorrhoeae is a major public health problem due to increasing incidence and antimicrobial resistance. Genetic markers of reduced susceptibility have been identified; the extent to which those are representative of global antimicrobial resistance is unknown. We evaluated the performance of whole-genome sequencing (WGS) used to predict susceptibility to ciprofloxacin and other antimicrobials using a global collection of N. gonorrhoeae isolates. Susceptibility testing of common antimicrobials and the recently developed zolifodacin was performed using agar dilution to determine minimum inhibitory concentrations (MICs). We identified resistance alleles at loci known to contribute to antimicrobial resistance in N. gonorrhoeae from WGS data. We tested the ability of each locus to predict antimicrobial susceptibility. A total of 481 N. gonorrhoeae isolates, collected between 2004 and 2019 and making up 457 unique genomes, were sourced from 5 countries. All isolates with demonstrated susceptibility to ciprofloxacin (MIC ≤0.06 μg/mL) had a wild-type gyrA codon 91. Multilocus approaches were needed to predict susceptibility to other antimicrobials. All isolates were susceptible to zoliflodacin, defined by an MIC ≤0.25 μg/mL. Single marker prediction can be used to inform ciprofloxacin treatment of N. gonorrhoeae infection. A combination of molecular markers may be needed to determine susceptibility for other antimicrobials.
Sections du résumé
BACKGROUND
Neisseria gonorrhoeae is a major public health problem due to increasing incidence and antimicrobial resistance. Genetic markers of reduced susceptibility have been identified; the extent to which those are representative of global antimicrobial resistance is unknown. We evaluated the performance of whole-genome sequencing (WGS) used to predict susceptibility to ciprofloxacin and other antimicrobials using a global collection of N. gonorrhoeae isolates.
METHODS
Susceptibility testing of common antimicrobials and the recently developed zolifodacin was performed using agar dilution to determine minimum inhibitory concentrations (MICs). We identified resistance alleles at loci known to contribute to antimicrobial resistance in N. gonorrhoeae from WGS data. We tested the ability of each locus to predict antimicrobial susceptibility.
RESULTS
A total of 481 N. gonorrhoeae isolates, collected between 2004 and 2019 and making up 457 unique genomes, were sourced from 5 countries. All isolates with demonstrated susceptibility to ciprofloxacin (MIC ≤0.06 μg/mL) had a wild-type gyrA codon 91. Multilocus approaches were needed to predict susceptibility to other antimicrobials. All isolates were susceptible to zoliflodacin, defined by an MIC ≤0.25 μg/mL.
CONCLUSIONS
Single marker prediction can be used to inform ciprofloxacin treatment of N. gonorrhoeae infection. A combination of molecular markers may be needed to determine susceptibility for other antimicrobials.
Identifiants
pubmed: 36735316
pii: 7025705
doi: 10.1093/infdis/jiad027
pmc: PMC10319951
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ciprofloxacin
5E8K9I0O4U
Anti-Infective Agents
0
Azithromycin
83905-01-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
917-925Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201300014I
Pays : United States
Organisme : NIAID NIH HHS
ID : K01 AI136725
Pays : United States
Organisme : FIC NIH HHS
ID : K01 TW012170
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132606
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH080634
Pays : United States
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIAID NIH HHS
ID : F32 AI145157
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Références
Emerg Infect Dis. 2016 Jan;22(1):65-7
pubmed: 26689114
J Clin Microbiol. 2007 Apr;45(4):1250-4
pubmed: 17267635
Ann N Y Acad Sci. 2019 Jan;1435(1):93-109
pubmed: 29876934
JAMA. 2013 May 15;309(19):1989
pubmed: 23677303
mBio. 2018 Aug 7;9(4):
pubmed: 30087172
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31871081
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80
pubmed: 22155830
Nucleic Acids Res. 2015 Feb 18;43(3):e15
pubmed: 25414349
J Antimicrob Chemother. 2019 Jul 1;74(7):1820-1824
pubmed: 30897201
J Antimicrob Chemother. 2021 Oct 11;76(11):2847-2849
pubmed: 34324655
JAMA. 2013 Jan 9;309(2):163-70
pubmed: 23299608
Emerg Infect Dis. 2011 Jan;17(1):148-9
pubmed: 21192886
Bull World Health Organ. 2019 Aug 01;97(8):548-562P
pubmed: 31384073
Expert Opin Pharmacother. 2009 Mar;10(4):555-77
pubmed: 19284360
Euro Surveill. 2011 Oct 27;16(43):
pubmed: 22085601
J Antimicrob Chemother. 2015 Sep;70(9):2536-42
pubmed: 26084303
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32571818
Euro Surveill. 2010 Nov 25;15(47):
pubmed: 21144442
J Antimicrob Chemother. 2015 Feb;70(2):374-81
pubmed: 25331059
Bioinformatics. 2016 Jan 15;32(2):292-4
pubmed: 26428292
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Sex Transm Dis. 2012 Apr;39(4):316-23
pubmed: 22421701
J Infect Dis. 2017 Feb 1;215(3):491
pubmed: 28003354
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1911-1916
pubmed: 33332296
Antimicrob Agents Chemother. 2014 May;58(5):2528-34
pubmed: 24514092
Lancet Infect Dis. 2014 Mar;14(3):220-6
pubmed: 24462211
Elife. 2020 Jun 30;9:
pubmed: 32602459
Sex Transm Dis. 2013 Nov;40(11):877-9
pubmed: 24113412
N Engl J Med. 2018 Nov 8;379(19):1835-1845
pubmed: 30403954
Euro Surveill. 2011 Apr 07;16(14):
pubmed: 21492528
Int J Antimicrob Agents. 2017 Feb;49(2):252-254
pubmed: 28038960
J Antimicrob Chemother. 2016 Nov;71(11):3096-3108
pubmed: 27432602
J Infect Dis. 2017 Nov 27;216(9):1141-1149
pubmed: 28968710
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Clin Microbiol Rev. 2014 Jul;27(3):587-613
pubmed: 24982323
Sex Transm Infect. 2015 Jun;91(4):232-3
pubmed: 25990778
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
PLoS One. 2014 Nov 19;9(11):e112963
pubmed: 25409509
Clin Infect Dis. 2021 Jul 15;73(2):298-303
pubmed: 32766725
BMC Infect Dis. 2015 Sep 17;15:378
pubmed: 26381611
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45
pubmed: 21576437
BMC Infect Dis. 2015 Aug 11;15:321
pubmed: 26259560
Future Microbiol. 2012 Dec;7(12):1401-22
pubmed: 23231489
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500